From Nisin to Programmable Lanthipeptide Preservatives: Biosynthesis-First Engineering for Food Antimicrobial Peptides

Abstract

Nisin demonstrates that ribosomally synthesized and post-translationally modified antimicrobial peptides can become practical food preservatives, but its success does not provide a universal route for next-generation peptide antimicrobials. Commenting on the compartmentalized lanthipeptide biosynthesis platform reported by Suo et al., this article argues for biosynthesis-first engineering, defined here as evaluating antimicrobial activity together with pathway compatibility, modification fidelity, host tolerance, recoverability, and food-matrix performance from the outset, rather than treating production and application constraints as downstream considerations. For lanthipeptides, antimicrobial activity must be considered together with precursor expression, post-translational modification, maturation, host compatibility, recovery, food-matrix stability, sensory neutrality, regulatory feasibility, and production cost. A sequence-to-biosynthesis-to-food framework can help distinguish peptides that are merely active in vitro from those that are realistic candidates for food preservation.

Keywords

Nisin / Lanthipeptides / Antimicrobial peptides / RiPPs / Food preservation / Biosynthesis-first engineering / Food-matrix validation

The article titled “Efficient production of nisin and diverse lanthipeptides in Escherichia coli through coordination of expression, modification, and maturation in a tailormade compartmentalized biosynthetic platform” by Suo et al., published in Chemical Engineering Journal (2026) provides valuable insights into the engineering of lanthipeptide biosynthesis and scalable antimicrobial peptide production [1]. This commentary offers additional perspectives on how such biosynthetic platforms could inform the development of food-relevant antimicrobial peptides, particularly nisin analogues and other lanthipeptides intended for preservation, microbial control, and food-grade biomanufacturing.

1 Nisin Proves Food Relevance, But Not Platform Generality

Nisin remains the best-known example of a peptide antimicrobial that has moved from microbial metabolism into food preservation. As a ribosomally synthesized and post-translationally modified peptide (RiPP), it belongs to the lanthipeptide family and owes much of its activity and stability to enzymatically installed thioether crosslinks [2,3]. Its practical applications span several food categories. In ricotta-type cheese, incorporation of nisin at 2.5 mg/L inhibited Listeria monocytogenes for at least eight weeks during refrigerated storage [4]. In vacuum-packaged ready-to-eat turkey ham, treatment with 0.5% nisin produced an initial 4.42-log reduction in L. monocytogenes and maintained counts below 2.75 log(CFU/g) over 63 days at 4 °C [5]. Nisin has also been incorporated into hurdle-processing strategies; when combined with high-pressure carbon dioxide and mild heat, it enabled complete inactivation of aerobic bacteria in litchi juice under the tested conditions [6]. These examples explain why nisin occupies a central position in discussions of bacteriocins, protective cultures, clean-label preservation, and pathogen control in dairy, meat, and other food systems [3].

Nevertheless, the success of nisin can be misleading if it is read as proof that the field already has a general solution. Nisin is not only a sequence with antimicrobial activity. It is the output of a coordinated biosynthetic and application system involving precursor expression, post-translational modification, leader processing, transport, producer immunity, recovery, formulation, and regulated use. The regulatory description of nisin preparation makes this point clearly: The approved ingredient is defined by its production source, activity, specifications, microbial limits, use level, and application context, not by peptide sequence alone [7]. For next-generation food antimicrobial peptides, especially nisin analogues and other lanthipeptides, the key question is therefore not simply whether a candidate inhibits an indicator strain. The more useful question is whether its biosynthetic machinery can be reconstructed, tuned, transferred, and scaled while retaining activity, stability, and safety in food-relevant environments.

This distinction matters because food antimicrobials face constraints that differ from those of therapeutic peptide antibiotics. A clinical peptide may justify high purification cost, narrow production batches, and expensive formulation. A food preservative usually cannot. It must be compatible with large-volume production, variable raw materials, complex matrices, low use levels, and stringent sensory expectations. Proteins, fat, salt, pH, thermal history, and storage conditions can all alter peptide solubility, diffusion, adsorption, and activity [8]. For example, in a laboratory cheese model, nisin initially reduced Listeria monocytogenes counts, but the pathogen subsequently grew during storage, and efficacy varied with cheese pH, storage temperature, and strain; strains with similar broth MICs also differed in their response in cheese, showing that in vitro susceptibility does not reliably predict performance in a food matrix [9]. A peptide that looks potent in broth may be much less useful if it binds strongly to casein or meat proteins, loses activity in a plant-based emulsion, disrupts starter cultures, or requires a purification route that is economically unrealistic. For this reason, peptide-based food preservation should begin with the coupled problem of sequence, biosynthesis, process, and matrix performance.

2 What the Suo et al. Study Adds

Suo et al. address a central bottleneck in lanthipeptide engineering: Active products require coordination of expression, modification, maturation, and recovery [1]. Although these steps are often optimized separately, they are mechanistically interdependent. The precursor must be expressed without imposing excessive host burden, recognized efficiently by the modifying enzymes, converted to the correct dehydration and cyclization pattern, and processed into a recoverable active product. The compartmentalized platform developed by Suo et al. is therefore more than a strategy for increasing yield; it treats the biosynthetic pathway as an integral part of product design. At the same time, it should be regarded as a powerful prototyping and production platform rather than a complete food-ingredient development workflow.

This framing is especially useful for food engineering. Genome mining, peptide databases, rational design, and AI-assisted discovery are expanding the number of candidate antimicrobial peptides faster than traditional production workflows can validate them [8,10]. The resulting risk is an expanding catalogue of active sequences with uncertain manufacturability or food applicability. Unlike conventional pipelines that prioritize sequence discovery and in vitro activity before addressing production, biosynthesis-first engineering evaluates activity together with pathway compatibility, modification fidelity, host tolerance, recovery, and food-matrix performance from the outset. Its principal advantages are earlier elimination of candidates with poor production potential, simultaneous optimization of peptide sequence and biosynthetic pathway, and earlier generation of process-relevant information such as mature peptide yield, modification fidelity, host burden, and recoverability. These features can reduce late-stage failure and make design–build–test cycles more predictive and efficient.

This approach also aligns with recent cell-free lanthipeptide work, in which Liu et al. reported the UniBioCat system for rapid RiPP biosynthesis and engineering; that study reconstituted a salivaricin B biosynthetic pathway, screened variants with enhanced antimicrobial activity, and produced ten previously uncharacterized lanthipeptides for bioactivity evaluation [11]. Cell-free approaches provide open reaction environments, easier adjustment of reaction conditions, improved mass transfer, and partial avoidance of cellular toxicity [11], whereas whole-cell systems such as the E. coli platform developed by Suo et al. remain important for production scale and process economics [1]. Together, these approaches could support rapid prototyping followed by scalable manufacture.

More broadly, peptide engineering cannot be separated from pathway engineering. Changing a core peptide residue may improve potency or selectivity, but it may also change enzyme recognition, modification efficiency, maturation, solubility, host burden, or recovery. Conversely, an improved biosynthetic environment may rescue a peptide that would otherwise appear unproductive. The peptide, leader sequence, modifying enzymes, maturation steps, host background, and recovery workflow should therefore be treated as a coupled design system rather than as sequential development steps.

3 Why This Matters for Food Antimicrobial Peptide Development

Food systems need antimicrobial control, but they do not always need broad killing. In fermented foods, dairy systems, ready-to-eat foods, meat products, and minimally processed foods, the desired outcome is often selective suppression of pathogens or spoilage organisms while preserving starter cultures, protective microbiota, flavor development, acidification, and texture formation [8,12]. Nisin and related bacteriocins are attractive in this context because their activity can be potent and their structures can be relatively stable, but they also illustrate why modified peptides are technically demanding. Thioether rings can improve stability, yet they require correct post-translational installation. Leader peptides can guide recognition, but they also create maturation and removal requirements. Producer immunity and transport can protect native hosts, but these functions may not transfer cleanly to heterologous platforms.

The Suo et al. study is therefore most significant when read as a platform paper rather than as a single-product paper. Nisin already provides the food anchor. The broader opportunity is to use engineered lanthipeptide biosynthesis to generate preservatives with more suitable activity windows, better matrix tolerance, improved production behavior, or more selective effects against food-relevant targets. This does not mean that every engineered lanthipeptide should be pushed toward food application. Many will fail for practical reasons. The point is to introduce these practical filters earlier. Can the candidate be modified correctly? Does it remain stable after processing and storage? Does it retain activity in cheese, meat, seafood, plant-based products, coatings, or packaging films? Does it affect sensory quality? Can it be produced as a purified ingredient, standardized fermentate, protective culture, or active packaging component? Does it preserve beneficial microbes where those microbes are part of the product? A peptide that is moderately active but easy to produce and stable in the target matrix may be more valuable than a highly potent peptide with poor maturation, poor recovery, or unacceptable sensory effects.

This perspective also helps place recent targeted and AI-assisted AMP studies in context. Cell-free biosynthesis combined with deep learning has already shown how rapidly candidate antimicrobial peptides can be designed, produced, and screened [10]. Phage-display and rational-design approaches have also produced targeted peptides for food-safety applications, including anti-E. coli strategies [13], and machine-learning workflows have accelerated discovery of antifungal peptides against Fusarium graminearum [14]. These studies are useful routes into sequence space, but they do not remove the need for biosynthesis and food-matrix evaluation. If anything, fast discovery increases the need for disciplined engineering filters, because it becomes easier to generate more candidates than can be meaningfully translated.

4 From Biosynthetic Platform to Food-Grade Translation

A successful biosynthetic platform is not automatically a food ingredient platform. E. coli is a powerful chassis for engineering and pathway prototyping, but food translation may require purified peptides, standardized antimicrobial fermentates, food-compatible hosts, or transfer of validated pathways into lactic acid bacteria, Bacillus, yeast, or other acceptable production systems. In some cases, E. coli may remain the best research chassis but not the final production organism. In others, extensive purification may make the host less important than the final specification. Either route demands attention to residual host-cell material, endotoxin risk where relevant, product identity, activity units, impurity profiles, batch reproducibility, and regulatory documentation [15]. Regulatory assessment will also depend on product format and jurisdiction, as purified additives, fermentation-derived ingredients, protective cultures, and packaging components may require different evidence on identity, purity, production organism, residual host material, safety, intended use level, and labeling [7,15].

This is where food engineering can add value beyond synthetic biology. Fig. 1 summarizes the proposed translation logic. The pipeline starts with genome mining, nisin-like scaffold engineering, and AI-assisted candidate selection, but the decision to advance a peptide should depend on more than inhibition zones or MIC values. Lanthipeptide candidates should pass through biosynthetic reconstruction, modification and maturation assessment, host-compatibility testing, recovery design, food-matrix challenge tests, sensory evaluation, safety assessment, and preliminary cost analysis. Modification fidelity and maturation efficiency should be treated as quantitative quality attributes. For food applications, matrix performance and safety should be decision gates rather than final demonstrations.

Recent work on modular bacteriocin secretion platforms also supports this broader design logic. Rutter et al. showed that engineered non-pathogenic E. coli strains can be used to express and secrete multiple bacteriocins, including Enterocin A and Enterocin B, for targeted antibacterial activity [16]. Although that study is framed mainly around engineered live biotherapeutics, the underlying lesson is relevant: secretion, delivery, and target ecology matter as much as peptide choice. For foods, the equivalent issue is whether a peptide can be delivered in the correct format, at the correct site, and with the correct selectivity. Precision fermentation and cell-free prototyping can accelerate this work, but food-grade translation still requires process specifications, safety dossiers, and evidence under realistic conditions [15].

5 Outlook

The broader implication of the Suo et al. study is that food antimicrobial peptide development should move from activity-first screening toward production-informed, pathway-guided engineering. Antimicrobial potency remains essential, but potency alone is a weak predictor of food utility. A future preservative peptide should be judged by whether its biosynthetic route, modification pattern, host compatibility, maturation, recovery, formulation, and matrix performance converge in a realistic application. Nisin shows that lanthipeptides can succeed in foods, but it should now serve as a platform reference rather than a single-product endpoint. Three priorities follow. First, lanthipeptide studies should report production and maturation metrics together with activity, including precursor conversion, modification fidelity, mature peptide yield, impurity profile, and batch variability. Second, candidate peptides should be tested earlier under food-relevant conditions, including pH, salt, fat, protein, temperature, storage, and interactions with starter cultures or protective microbiota. Third, food-grade translation should be considered at the design stage, whether the intended product is a purified peptide, standardized fermentate, protective culture, coating, or packaging component.

A further issue is terminology. In food contexts, words such as natural, fermented, engineered, purified, and cell-free do not carry the same regulatory or consumer meaning. A peptide discovered from a food-associated microbe, produced in E. coli, purified chromatographically, and then added to a ready-to-eat product is a different proposition from the same sequence produced in situ by a protective culture. The science may regard these as related production formats, but regulators, manufacturers, and consumers may not. For that reason, the product format should be fixed earlier than is common in discovery studies. Without that decision, the same promising peptide can drift between incompatible assumptions about purity, labeling, delivery, and cost.

The next generation of food antimicrobial peptides will not come from discovering active sequences alone. It will come from reliable sequence-to-biosynthesis-to-food pipelines. Suo et al. provide a useful step in that direction by showing how expression, modification, and maturation can be coordinated in a tailored biosynthetic platform [1]. The challenge now is to connect such platforms to food-compatible production routes and matrix-specific validation. This is a food-engineering problem in the strict sense: the relevant question is not only what a molecule can do, but whether it can be produced, specified, validated, and used safely in the foods where it is expected to work.

References

[1] Suo F Y, Zhu H H, Shen Y. et al. Efficient production of nisin and diverse lanthipeptides in Escherichia coli through coordination of expression, modification, and maturation in a tailormade compartmentalized biosynthetic platform. Chemical Engineering Journal, 2026, 535: 175479

[2] Field D, Fernandez De Ullivarri M, Ross RP. et al. After a century of nisin research—where are we now?. FEMS Microbiology Reviews, 2023, 47(3): fuad023

[3] Yuan L, Wu S B, Tian K R. et al. Nisin-relevant antimicrobial peptides: synthesis strategies and applications. Food & Function, 2024, 15(19): 9662–9677

[4] Davies E A, Bevis H E, Delves-Broughton J. The use of the bacteriocin, nisin, as a preservative in ricotta-type cheeses to control the food-borne pathogen Listeria monocytogenes. Letters in Applied Microbiology, 1997, 24(5): 343–346

[5] Ruiz A, Williams S K, Djeri N. et al. Nisin, rosemary, and ethylenediaminetetraacetic acid affect the growth of Listeria monocytogenes on ready-to-eat turkey ham stored at four degrees Celsius for sixty-three days. Poultry Science, 2009, 88(8): 1765–1772

[6] Li H, Zhao L, Wu J H. et al. Inactivation of natural microorganisms in litchi juice by high-pressure carbon dioxide combined with mild heat and nisin. Food Microbiology, 2012, 30(1): 139–145

[7] LII. 21 CFR § 184.1538— Nisin preparation. Ithaca: LII, n.d.

[8] Jiao Z Y, Sheng L N, Sun X L. Advances in antimicrobial peptides for food systems: a review of applications, species-specific targets, and strategies to enhance specificity. Trends in Food Science & Technology, 2025, 165: 105348

[9] Henderson L O, Erazo Flores B J, Skeens J. et al. Nevertheless, she resisted – role of the environment on Listeria monocytogenes sensitivity to nisin treatment in a laboratory cheese model. Frontiers in Microbiology, 2020, 11: 635

[10] Pandi A, Adam D, Zare A. et al. Cell-free biosynthesis combined with deep learning accelerates de novo-development of antimicrobial peptides. Nature Communications, 2023, 14(1): 7197

[11] Liu W Q, Ji X Y, Ba F. et al. Cell-free biosynthesis and engineering of ribosomally synthesized lanthipeptides. Nature Communications, 2024, 15(1): 4336

[12] Pujato S A, Mercanti D J, Briggiler Marcó M. et al. Bacteriocins from lactic acid bacteria: strategies for the bioprotection of dairy foods. Frontiers in Food Science and Technology, 2024, 4: 1439891

[13] Hu M Y, Li Y W, Cha S N. et al. Development of targeted antimicrobial peptides for Escherichia coli: combining phage display and rational design for food safety application. Food Chemistry, 2025, 470: 142685

[14] Ran Y, Li S, Wang Y J. et al. AI-accelerated identification of novel antimicrobial peptides for inhibiting Fusarium graminearum. Journal of Agricultural and Food Chemistry, 2025, 73(28): 17471–17482

[15] Sturme M, van der Berg J P, Kleter G. Precision Fermentation: with A Focus on Food Safety. Rome: Food and Agriculture Organization of the United Nations, 2025

[16] Rutter J W, Dekker L, Clare C. et al. A bacteriocin expression platform for targeting pathogenic bacterial species. Nature Communications, 2024, 15(1): 6332

RIGHTS & PERMISSIONS

The Author(s) 2026. This article is published by Higher Education Press.